Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.

Acta neuropathologica communications - 21 Jan 2015

Pellegatta Serena, Valletta Lorella, Corbetta Cristina, Patanè Monica, Zucca Ileana, Riccardi Sirtori Federico, Bruzzone Maria Grazia, Fogliatto Gianpaolo, Isacchi Antonella, Pollo Bianca, Finocchiaro Gaetano

Abstract excerpt

The R132H mutation of cytosolic isocitrate dehydrogenase (IDH1) is present in the majority of low grade gliomas.Immunotherapy in these tumors has an interesting, still unexploited, therapeutic potential, as they are less immunosuppressive than glioblastomas. Using site-directed mutagenesis we int...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Transforming Growth Factor beta2
Share to Gas Chromatography-Mass Spectrometry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutarates

Share to Granzymes

Share to Immunotherapy

Share to Interleukin-10

Share to Isocitrate Dehydrogenase

Share to Perforin

Source

Open in PubMed Open full text

Identifiers

PMID: 25849072
DOI: 10.1186/s40478-014-0180-0
PMCID: PMC4359524

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25849072-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.PMID 25849072Read ↗

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma ImmunitySemantic proximity Read ↗

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in miceSemantic proximity Read ↗

A vaccine targeting mutant IDH1 induces antitumour immunity.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomasSemantic proximity Read ↗

A vaccine targeting mutant IDH1 in newly diagnosed glioma.Semantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Treating depression in later lifeSemantic proximity Read ↗

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.